Anticancer

Gamabufotalin
Catalog No: CFN90212

Gamabufotalin has been used for treatment of COX-2-mediated diseases and cancer therapy, it triggers c-Myc degradation via induction of WWP2 in multiple myeloma(MM) cells. Gamabufotalin strongly inhibit cancer cell growth and inflammatory response, it inhibits angiogenesis by inhibiting the activation of VEGFR-2 signaling pathways and could be a potential candidate in angiogenesis-related disease therapy.

Aristolactam AIIIa
Catalog No: CFN97551

Aristolactam AIIIa is a new type of Plk1 inhibitors, targeting the Polo Box domain (PBD), it has anti-tumor activity. Aristolactam IIIa shows inhibition of platelet aggregation induced by collagen or arachidonic acid.

1-O-Acetyl britannilactone
Catalog No: CFN90219

1-O-Acetyl britannilactone shows antifungal, and anti-cancer activities, it suppresses angiogenesis and lung cancer cell growth possibly via regulating the VEGFR-Src-FAK signaling. 1-O-Acetyl britannilactone may be one anti-inflammatory drug which inhibits the expression of COX-2 gene by blocking NF-κB activation and thus suppresses the inflammatory response to LPS in vascular smooth muscle cells.

Britannin
Catalog No: CFN90220

Britannin has strong cytotoxicity to HepG-2, MCF-7, MDBK and A-549 cells (IC50: 2.2, 5.9, 5.4, and 3.5 microg/mL, respectively). Britannin inhibits growth of MCF-7 and MDA-MB-468 breast cancer cells through the activation of the mitochondrial apoptotic pathway and may potentially serve as an agent for breast cancer therapy.

Beta-boswellic acid
Catalog No: CFN90221

Beta-boswellic acid and its derivatives (the major constituents of Boswellin) have anti-carcinogenic, anti-tumor, and anti-hyperlipidemic activities. Beta-boswellic acid can significantly enhance neurite outgrowth, branching, and tubulin polymerization dynamics.